Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Sensitivity to Particle Size in Mometasone Furoate Nasal Spray
NCT02588326Phase 1Completed
- Sponsor
- University of Florida
- Start
- Sep 2018
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mometasone furoate nasal spray in allergic rhinitis (AR) (2 arms), sponsored by University of Florida. Primary endpoint: Area under the plasma concentration versus time curve at 14 hours. Started Sep 2018; status: completed.
02
Drugs
mometasone furoate nasal spray
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT02588326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02588326.